Abstract
Obesity is a chronic pathological condition characterized by an increased body fat accumulation to the extent that it may have an adverse effect on the health. Depression is the most common co-morbidity of obesity, which may cause the Binge Eating Disorder (BED), leading to morbid obesity. In the present project a dispersible 60mg Orlistat (ORST) and β-cyclodextrin (β-CD), (1:2M) complexed core tablet is press coated with the taste masked 75mg Venlafaxine Hcl. (VLFXN) microparticles, prepared with Eudragit EPO(1:3), by emulsification solvent evaporation method, to obtain the chewable tablet-in-tablet dosage form. A Reverse phase (RP)-HPLC method was developed for the simultaneous estimation of ORST and VLFXN in the formulation. The optimized formulation was palatable and there was no drug excipients interaction which was confirmed by IR Spectrum. Press coated, tablet-in-tablets were evaluated for physicochemical properties. All the values obtained were within the standard limits. And in the in-vitro dissolution study the release of both drugs, ORST and VLFXN at the end of 15mins was found to be 86% and 92% respectively. Hence, the developed chewable tablet-in-tablet formulation of ORST and VLFXN can be a viable drug delivery system for treating patients with obesity and BED.
Highlights
Tablets are the most popular dosage form and threefourth of the total medicine is dispensed in the form of tablets
In the present project a dispersible 60mg Orlistat (ORST) and β-cyclodextrin (β-CD), (1:2M) complexed core tablet is press coated with the taste masked 75mg Venlafaxine Hcl. (VLFXN) microparticles, prepared with Eudragit EPO (1:3), by emulsification solvent evaporation method, to obtain the chewable tablet-in-tablet dosage form
The developed formulation was designed to enhance the solubility of ORST and mask the bitter taste of VLFXN and prepare a chewable press coated, tablet-in-tablet
Summary
Tablets are the most popular dosage form and threefourth of the total medicine is dispensed in the form of tablets. For those people who have swallowing problems, chewable tablets are the best alternative and most widely used chewable dosage form (Lachman, et al, 1987 and Mary Kathryn et al, 2002). A compression-coated tablet is a solid dosage form, in which all the surface of an inner core tablet is completely surrounded by coat layers. Compression coating is mainly used to develop the combination of drugs and to protect the hygroscopic or unstable drug in the core by coating with the stable outer layers, The drawback of compression coating, i.e., keeping the core tablet in the centre of the compression-coated tablets and absence of core in the coat, have been overcome by using novel
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
